Want to see HK:2453 full AI Analyst Report?
2453 Stock Chart & Stats
HK$1.83
-HK$0.24(-2.76%)
At close: 4:00 PM EST
HK$1.83
-HK$0.24(-2.76%)
Day’s Range― - ―
52-Week RangeHK$0.63 - HK$5.72
Previous CloseN/A
Volume2.50M
Average Volume (3M)590.21K
Market Cap
HK$693.54M
Enterprise ValueHK$4.18K
Total Cash (Recent Filing)HK$319.01M
Total Debt (Recent Filing)HK$3.09B
Price to Earnings (P/E)―
Beta0.59
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding313,874,630
10 Day Avg. Volume440,520
30 Day Avg. Volume590,206
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.62
Price to Sales (P/S)2.55
P/FCF Ratio-4.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Oncology-focused Healthcare PlatformAn integrated oncology offering across hospital operations, clinical infrastructure, equipment and consumables can deepen provider relationships and support recurring service activity as customers expand treatment capacity.
2025 Revenue ReboundThe return to double-digit revenue growth indicates improved commercial activity and provides a larger operating base. Sustaining this recovery would strengthen the platform’s ability to absorb fixed costs and improve future earnings quality.
Gross Margin RecoveryA positive gross margin is an important step toward economic viability, suggesting that service and product revenue covered direct costs in 2025. Further improvement could support operating leverage if revenue growth persists.
Bears Say
Persistent Operating LossesDeep operating and net losses show that the business has not yet demonstrated sustainable earnings power. Continued losses can constrain reinvestment, weaken resilience and make profitability dependent on significant execution improvements.
Weak Cash ConversionNegative operating and free cash flow means reported revenue growth is not translating into internally funded operations. If this pattern continues, the company may require additional financing to support losses and investment needs.
Elevated LeverageLeverage remains high relative to the company’s loss-making profile and limits financial flexibility. Debt obligations may restrict investment capacity and increase refinancing or funding pressure while returns on equity remain negative.
Concord Healthcare Group Co., Ltd. Class H News
2453 FAQ
What was Concord Healthcare Group Co., Ltd. Class H’s price range in the past 12 months?
Concord Healthcare Group Co., Ltd. Class H lowest stock price was HK$0.63 and its highest was HK$5.72 in the past 12 months.
What is Concord Healthcare Group Co., Ltd. Class H’s market cap?
Concord Healthcare Group Co., Ltd. Class H’s market cap is HK$693.54M.
When is Concord Healthcare Group Co., Ltd. Class H’s upcoming earnings report date?
Concord Healthcare Group Co., Ltd. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 219 days.
How were Concord Healthcare Group Co., Ltd. Class H’s earnings last quarter?
Concord Healthcare Group Co., Ltd. Class H released its earnings results on Aug 21, 2026. The company reported -HK$0.112 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Concord Healthcare Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Concord Healthcare Group Co., Ltd. Class H’s price is currently Overvalued.
Does Concord Healthcare Group Co., Ltd. Class H pay dividends?
Concord Healthcare Group Co., Ltd. Class H does not currently pay dividends.
What is Concord Healthcare Group Co., Ltd. Class H’s EPS estimate?
Concord Healthcare Group Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Healthcare Group Co., Ltd. Class H have?
Concord Healthcare Group Co., Ltd. Class H has 313,874,630 shares outstanding.
What happened to Concord Healthcare Group Co., Ltd. Class H’s price movement after its last earnings report?
Concord Healthcare Group Co., Ltd. Class H reported an EPS of -HK$0.112 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.907%.
Which hedge fund is a major shareholder of Concord Healthcare Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2453
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Concord Healthcare Group Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.59%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.55%
Trailing 12-Months
Company Description
Concord Healthcare Group Co., Ltd. Class H
Concord Healthcare Group Co., Ltd. is dedicated to providing comprehensive cancer treatment services for patients and healthcare institutions throughout China. Its operations extend beyond direct care to include the distribution and installation of medical hardware and software, along with offering management and technical assistance, and providing equipment via operating leases. The company was founded in 2008 and is headquartered in Beijing, China. It functions as a subsidiary of Shanghai Medstar Financial Leasing Company.
Technical Analysis
C-MER Eye Care Holdings Limited
―
Hospital Corporation of China Ltd
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
Arrail Group Ltd.
―